# Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

Source: https://onco.cc/trials/nct06780098/  
OnCo record `nct06780098` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Docetaxel in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) is a phase 2 interventional study registered as NCT06780098 by Merck Sharp & Dohme LLC, with 144 participants planned, started 2025-05-28 and due to reach its primary completion in 2032-03-02. Interventions recorded: R-DXD, I-DXD, Docetaxel, Rescue Medications and Rescue Medication.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06780098
- Phase: 2
- Setting: KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 144

## Sources

- ClinicalTrials.gov NCT06780098: https://clinicaltrials.gov/study/NCT06780098

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06780098.json